Evidence map›Paper›PMID 27447042›Full record

ArticleCell chemical biology2016

At Long Last Potent and Selective KDM5 Inhibitors.

Dante Rotili, Andrea Mattevi

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cell chemical biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Small molecule KDM4s inhibitors as anti-cancer agents.Journal of enzyme inhibition and medicinal chemistry · 2018
    Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Dante RotiliDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, 00185 Rome, Italy. Electronic address: dante.rotili@uniroma1.it.
Andrea MatteviDepartment of Biology and Biotechnology, University of Pavia, 27100 Pavia, Italy. Electronic address: andrea.mattevi@unipv.it.
Sapienza University of Rome · ITUniversity of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histone lysine demethylase 5 enzymes (KDM5s) have recently been proposed as crucial oncogenic drivers. In this issue of Cell Chemical Biology, Horton et al. (2016) describe results of an extensive structural analysis that reveals how distinct inhibitor chemotypes bind KDM5 and suggest avenues for improving KDM5 inhibitory potency and selectivity.

Indexed as

HistonesLysineHistonesLysine

Identifiers

PMID27447042
OpenAlexW2483055127

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.